ReviewCancer2023

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.

Liza C Villaruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.